论文部分内容阅读
目的:分析布地奈德对支气管哮喘急性发作且伴有感染患儿的疗效及对肺功能指标的影响.方法:将本院收治的96例支气管哮喘急性发作且伴有感染的患儿作为研究对象,随机分为对照组和观察组各48例,两组患儿均给予常规抗感染治疗,对照组给予地塞米松雾化吸入,观察组给予布地奈德雾化吸入,比较两组患儿临床疗效和治疗前、治疗后1周第1秒用力呼气容积(FEV1)、FEV1占预计值百分比(FEV1％)、肺活量(VC)、用力肺活量(FVC)等肺功能指标的改善状况及不良反应的发生情况.结果:观察组治疗总有效率为95.83％,高于对照组的72.92％(P＜0.05).两组患儿治疗后1周肺功能指标FEV1、FEV1％、VC、FVC水平较治疗前均升高,且观察组各指标水平均显著高于对照组(P均＜0.01).观察组患儿不良反应发生率(4.17％)低于对照组(18.75％)(P＜0.05).结论:布地奈德联合常规抗感染对治疗支气管哮喘急性发作且伴有感染的患儿具有良好的临床疗效,可有效改善FEV1、FEV1％等肺功能指标,且不良反应发生率较低,具有较高的安全性,因此具有良好的临床应用价值.“,”Objective: To analyze the efficacy of budesonide in treatment of children with acute asthma attack and infection and the effects on pulmonary function. Methods: Ninety-six children with acute asthma attack and infection admitted into our hospital were selected to be randomly divided into control group and observation group, with 48 cases in each. Two groups were given conventional therapy, the control group was additionally treated with dexamethasone aerosol inhalation, and the observation group additionally received budesonide aerosol inhalation. The clinical efficacy and the improvement of pulmonary function indexes including forced expiratory volume in one second ( FEV1), FEV1 predicted ( FEV1％), vital capacity ( VC), forced vital capacity ( FVC) before and after treatment of one week and the incidence of adverse drug reactions in two groups were compared. Results: The total effective rate of observation group was 95.83％, significantly higher than that of control group 72.92％ ( P＜0.05) . The levels of FEV1, FEV1％, VC and FVC in two groups were significantly higher than those before treatment, and the levels of all indexes in observation group were significantly higher than those in control group ( P＜0.05) . The incidence of adverse drug reactions in observation group ( 4.17％) was significantly lower than that in control group (18.75％) ( P＜0.05) . Conclusion: The efficacy of budesonide combined with conventional therapy in the treatment of children with acute asthma attack and infection is significant, which can effectively improve the pulmonary function indexes such as FEV1 and FEV1％ with lower incidence of adverse drug reactions and higher safety; therefore, it has better clinical application value.